Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ViatrisXSWX:VTRS 60 Equity-to-Asset is 0.41 as of Jun. 2026, which is 8% above its 10-year median of 0.38. GuruFocus rates XSWX:VTRS with a GF Score™ of 60/100 and a GF Value™ of CHF9.10. The stock has 8 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Viatris ranks worse than 73.63% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Viatris's Total Stockholders Equity for the quarter that ended in Jun. 2026 was CHF11,398 Mil. Viatris's Total Assets for the quarter that ended in Jun. 2026 was CHF28,011 Mil.
Therefore, Viatris's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.41.
The historical rank and industry rank for Viatris's Equity-to-Asset or its related term are showing as below:
XSWX:VTRS'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.32 Med: 0.38 Max: 0.45
Current: 0.41
During the past 13 years, the highest Equity to Asset Ratio of Viatris was 0.45. The lowest was 0.32. And the median was 0.38.
XSWX:VTRS's Equity-to-Asset is ranked worse than 73.63% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs XSWX:VTRS: 0.41
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Viatris Equity-to-Asset Related Terms
Viatris Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Viatris's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:VTRS vs UTHR, NBIX, ELAN: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Viatris's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Viatris's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris (XSWX:VTRS) has a Equity-to-Asset of 0.41 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Viatris and its competitors. This is near median its historical median of 0.38. Over the past decade, Viatris' Equity-to-Asset has ranged from 0.32 to 0.45. According to the industry distribution chart, Viatris ranks #740 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 73.6%.
Is Viatris' Equity-to-Asset too high?
Viatris' current Equity-to-Asset of 0.41 is near median its 10-year median of 0.38. Over the past 10 years, this metric has ranged from a low of 0.32 to a high of 0.45. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Viatris' value of 0.41 is 31.7% below this industry median. Based on the distribution chart, Viatris ranks #740 out of 1005 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Viatris has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Viatris' Equity-to-Asset compare to UTHR and NBIX?
According to the Drug Manufacturers industry distribution chart, Viatris ranks #740 out of 1005 companies for Equity-to-Asset. This places Viatris in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Viatris' value of 0.41 is 31.7% below this benchmark. Historically, Viatris' own Equity-to-Asset has ranged from 0.32 to 0.45 over the past decade. While the company's 10-year median is 0.38 vs. the industry median of 0.60, Viatris has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viatris's current Equity-to-Asset of 0.41 is 31.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Viatris and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viatris's current Equity-to-Asset is 0.41, which is near median its own 10-year median of 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Viatris (XSWX:VTRS) has a current Equity-to-Asset of 0.41. The stock's GF Value™ is CHF9.10, compared to a current price of CHF13.01 — trading 42.9% above its estimated fair value. The current Equity-to-Asset is 0.41, which is near median its 10-year median of 0.38 and 31.7% below the Drug Manufacturers industry median of 0.60. Viatris' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Viatris (XSWX:VTRS), the current Equity-to-Asset is 0.41 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viatris (XSWX:VTRS) Overvalued in 2026?
Based on GuruFocus' analysis, Viatris stock appears to be overvalued.
The current stock price of CHF13.01 is trading 42.9% above its estimated GF Value™ of CHF9.10.
Key valuation signals for XSWX:VTRS:
Equity-to-Asset: 0.41 (near median its 10-year median of 0.38)
GF Value™: CHF9.10 vs. price of CHF13.01 (42.9% above fair value)
Industry Position: 31.7% below the Drug Manufacturers median (#740 of 1005)
No single metric tells the full story. See the XSWX:VTRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
60GF Score
Get the complete analysis for XSWX:VTRS
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:VTRS has been successfully added to your 
